Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by Blair William & Co. IL

Blair William & Co. IL boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 34,035 shares of the medical equipment provider’s stock after purchasing an additional 671 shares during the period. Blair William & Co. IL’s holdings in Zimmer Biomet were worth $3,694,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its holdings in shares of Zimmer Biomet by 12.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,642,801 shares of the medical equipment provider’s stock valued at $1,404,638,000 after buying an additional 1,215,935 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Zimmer Biomet by 12.6% in the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock valued at $701,521,000 after buying an additional 722,041 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of Zimmer Biomet by 6.7% in the second quarter. Victory Capital Management Inc. now owns 3,364,624 shares of the medical equipment provider’s stock valued at $365,163,000 after buying an additional 211,637 shares in the last quarter. Van ECK Associates Corp increased its holdings in shares of Zimmer Biomet by 5.3% in the second quarter. Van ECK Associates Corp now owns 3,325,598 shares of the medical equipment provider’s stock valued at $360,927,000 after buying an additional 167,038 shares in the last quarter. Finally, Boston Partners increased its holdings in shares of Zimmer Biomet by 26.3% in the first quarter. Boston Partners now owns 3,314,939 shares of the medical equipment provider’s stock valued at $437,413,000 after buying an additional 691,191 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ZBH has been the topic of several research reports. Wolfe Research initiated coverage on Zimmer Biomet in a report on Tuesday, September 10th. They issued a “peer perform” rating on the stock. Oppenheimer cut their target price on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Piper Sandler downgraded shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating and cut their target price for the company from $140.00 to $115.00 in a research note on Monday, July 1st. Evercore ISI reissued an “in-line” rating and set a $113.00 target price on shares of Zimmer Biomet in a research note on Thursday, September 5th. Finally, UBS Group cut their target price on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a research note on Thursday, August 8th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average price target of $125.17.

Zimmer Biomet Trading Up 0.1 %

Zimmer Biomet stock opened at $106.42 on Monday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 0.63. The company has a market capitalization of $21.89 billion, a price-to-earnings ratio of 23.03, a PEG ratio of 1.96 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $133.90. The company’s fifty day moving average price is $109.83 and its two-hundred day moving average price is $115.38.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, topping the consensus estimate of $1.99 by $0.02. The firm had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.94 billion. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.82 earnings per share. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.02 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.90%. The ex-dividend date of this dividend is Monday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 20.78%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.